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Background: The increased incidence of malignant melanoma in recent decades, along with 
its high mortality rate and pronounced resistance to therapy pose an enormous challenge. Novel 
therapeutic strategies, such as immunotherapy and targeted therapy, are urgently needed for 
melanoma. In this study, a new active targeting drug delivery system was constructed to combine 
chemotherapy and active speciﬁc immunotherapy.
Methods: The chemotherapeutic drug, dacarbazine (DTIC), that induces apoptosis through the 
intrinsic pathway which typically responds to severe DNA damage, was used as a model drug to 
prepare DTIC-loaded polylactic acid (PLA) nanoparticles (DTIC-NPs), which were covalently 
conjugated to a highly speciﬁc targeting functional TRAIL-receptor 2 (DR5) monoclonal anti-
body (mAb) that can contribute directly to cancer cell apoptosis or growth inhibition through 
the extrinsic pathway.
Results: Our in vitro experiments demonstrated that DTIC-PLA-DR5 mAb nanoparticles 
(DTIC-NPs-DR5 mAb) are an active targeting drug delivery system which can speciﬁcally 
target DR5-overexpressing malignant melanoma cells and become efﬁciently internalized. 
Most strikingly, compared with conventional DTIC-NPs, DTIC-NPs-DR5 mAb showed 
signiﬁcantly enhanced cytotoxicity and increased cell apoptosis in DR5-positive malignant 
melanoma cells.
Conclusion: The DTIC-NPs-DR5 mAb described in this paper might be a potential formulation 
for targeting chemotherapy and immunotherapy to DR5-overexpressing metastatic melanoma.
Keywords: malignant melanoma, DR5 monoclonal antibodies, dacarbazine, apoptosis, 
chemoimmunotherapy, active targeting nanoparticles
Introduction
Malignant melanoma is the most aggressive form of skin cancer, causing the major-
ity of skin cancer deaths. The past ﬁve decades have witnessed a steady and rapid 
rise in the incidence of malignant melanoma in developed countries.1 In the US, an 
estimated 68,700 new cases of melanoma occurred in 2009, with 8650 deaths from 
malignant melanoma.2 Despite a greater understanding of the risk factors as well as 
the genetic and epigenetic causes of melanoma, the death rate from melanoma con-
tinues to increase faster than the death rate for most other types of cancer.3 Common 
treatments for malignant melanoma involve a combination of therapies, including 
surgical removal, chemotherapy, and radiotherapy. However, at least one third of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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patients with early-stage melanoma will develop metastases, 
and the prognosis for patients with metastatic melanoma 
remains dismal. These patients have a median survival of 
approximately 6–8 months, and less than 5% will survive 
for ﬁve years or more.4 Accumulated genetic, functional, 
and biochemical studies suggest that melanoma cells become 
“bullet proof” against a variety of chemotherapeutic drugs by 
exploiting their intrinsic resistance to apoptosis and survival 
pathways during progression of melanoma.5 To date, no agent 
has achieved a clinically meaningful prolongation of overall 
survival.6–8 Thus, novel therapeutic strategies for melanoma 
are still sought, and there is a critical need for the develop-
ment of therapeutic agents that can target aberrant survival 
pathways in metastatic melanoma to improve the treatment 
of this disease.9,10
In recent years, new strategies for cancer treatment based 
on drug-loaded nanoparticulate formulations have emerged. 
Nanoparticles represent promising drug carriers, especially 
for speciﬁc transport of anticancer drugs to the tumor site, 
which can improve therapeutic efﬁcacy and reduce systemic 
toxicity.11,12 Nanoparticles have high drug-loading efﬁciency, 
with minor drug leakage and good storage stability, and may 
circumvent multidrug resistance in cancer cells.13 Polylactic 
acid (PLA) nanoparticles have good biodegradability and 
compatibility, are regarded as safe drug vectors, are widely 
used in drug delivery, and have been widely studied as an 
intravenously injectable drug vector.14–17 Meanwhile, some 
nanodrugs based on PLA nanoparticles have received funding 
to be clinically studied and some have been approved by the 
FDA after clinical studies.18,19 Nanoparticles can be delivered 
to tumor tissues by the enhanced permeability and retention 
effect,20 ie, passive targeting. Moreover, their biodistribution 
and permeability in tissues can be controlled by their size 
and surface properties.21 To obtain better selectivity and to 
enhance the uptake of nanoparticles by tumor cells, nanopar-
ticles are often functionalized with ligands, such as antibody 
fragments or peptides. By combining nanoparticles with the 
tumor-targeting properties of ligands, nanoparticles offer the 
promise of speciﬁc and efﬁcient active targeting delivery to 
tumor cells.22–25 Monoclonal antibodies (mAb) offer great 
potential as drug-targeting ligands.26
Tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL), a member of the tumor necrosis factor superfamily, 
is a promising agent for cancer therapy because of its ability 
to induce apoptosis in a variety of human cancer cell lines, but 
not in most normal cells.27,28 TRAIL transmits an apoptotic 
signal via two death receptors, ie, TRAIL-receptor1 (DR4) 
and TRAIL-receptor2 (DR5). Although there are additional 
receptor proteins (TRAIL-receptor3, TRAIL-receptor4, 
and osteoprotegerin) that can bind to TRAIL, these recep-
tors lack functional death domains and do not transmit the 
apoptotic signal.29 Agonistic mAb targeting TRAIL-R1 and 
TRAIL-R2 selectively exhibit potent antitumor activity in 
vivo, with better stability, a longer half-life, and less toxicity 
than TRAIL.30–33 Consequently, DR4 and DR5 appear to be 
an ideal target for both active and passive immunotherapy.
In this study, to overcome the limitations of the current 
therapy strategies, a new active targeting drug delivery system 
comprising dacarbazine (DTIC)-loaded PLA-DR5 mAb 
nanoparticles (DTIC-NPs-DR5 mAb) was constructed to 
combine chemotherapy and active speciﬁc immunotherapy 
in an optimal manner. DTIC was used as the model drug to 
prepare DTIC-NPs, which were covalently conjugated with 
DR5 mAb by a two-step carbodiimide (EDC) method. We then 
evaluated the characterization of active targeting nanoparticles 
in detail, with DTIC loading efﬁciency and DR5 conjugation 
ratios determined and deﬁned. The binding and uptake of 
fluorescently-labeled DR5 functionalized nanoparticles into 
malignant (A375) melanoma cells overexpressing the DR5 
receptor, as well as a DR5 underexpressing (NIH) ﬁbroblast 
cell line, was determined using confocal microscopy and flow 
cytometry. Cytotoxicity and cellular apoptosis assays using 
these nanoparticles and appropriate controls for melanoma 
cells and normal ﬁbroblasts were also studied. This study is 
expected to provide guidance regarding how best to combine 
DR5 mAb with existing cancer therapeutic agents to improve 
available treatment modalities for malignant melanoma and 
other cancer therapies. In this study, to overcome the limitations 
of the current therapy strategies, a new active targeting drug 
delivery system of DTIC-NPs-DR5 mAb was constructed to 
combine chemotherapy and active speciﬁc immunotherapy in 
an optimal manner.
Materials and methods
Materials
PLA (molecular weight 3000) was obtained from Shandong 
Institute of Medical Instruments (Shangdong, China). 
Human serum albumin or 3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyl tetrazolium bromide (MTT) was purchased from 
Sigma Chemical Co (St Louis, MO). DTIC was purchased 
from Suzhou Lixin Pharmaceutical Co (Suzhou, China). 
Humanized anti-DR5 mAb was purchased from Santa Cruz 
Biotechnology Inc (Santa Cruz, CA). A micro bicinchoninic 
acid protein assay kit was obtained from Pierce Chemical 
Company (Fort Pierce, FL). The human A375 malignant 
melanoma cell line and mice ﬁbroblast NIH cell line were International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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maintained in the International Joint Cancer Institute, 
Second Military Medical University (Shanghai, China). 
  Dulbecco’s Modiﬁed Eagle’s Medium and fetal bovine serum 
was   purchased from Hyclone Co (Logan, UT). Dimethyl 
sulfoxide, dichloromethane, acetone, and methanol were 
purchased from China National Medicine Corporation Ltd 
(Shanghai, China). The other chemicals used in this work 
were all analytical pure grade and used as received.
Preparation of antibody-modiﬁed  
nanoparticles
The DTIC-NPs were prepared using the double emul-
sion (w/o/w) and solvent evaporation method with minor 
modiﬁcation.34 Briefly, 100 µL of an aqueous solution of 
DTIC (w1) was emulsiﬁed using a 1 mL mixture of methylene 
dichloride and acetone (3:2, v/v) containing 10 mg of PLA 
polymers by an ultrasonic processor (100 W, 60 seconds, 
Branson Sonicator® 450) in an ice bath to form the ﬁrst emul-
sion (w1/o). The w1/o emulsion was then poured into 4 mL of 
human serum albumin solution (w2, 1%, w/v). This mixture 
was sonicated for 1 minute (100 W, 30 seconds × 2) to form 
a double emulsion (w1/o/w2). The w1/o/w2 double emulsion 
was then diluted in 30 mL 0.3% human serum albumin solu-
tion and stirred at room temperature for 4 hours to evaporate 
the organic phase. The resulting nanoparticles were puriﬁed 
and obtained by centrifugation at 16,000 rpm for 30 minutes 
(L-100XP, Beckman Coulter, Fullerton, CA) and washed 
three times before lyophilization (V2 K VirTis Inc, Gardiner, 
NY). The phycoerythrin (PE)-loaded PLA nanoparticles 
(PE-NPs) were prepared by the same method and blank PLA 
nanoparticles (PLA-NPs) were prepared according to the 
abovementioned method but omitting the DTIC.
conjugation of Dr5 monoclonal  
antibodies to nanoparticles
DR5 mAb conjugation was developed using the coupling 
strategy for DR5 mAb and PLA nanoparticles with EDC 
as the coupling agent. Briefly, 1 mL of PLA nanoparticle 
suspension (5 mg/mL, pH 7.4) was incubated with 50 µL 
of 50 mg/mL EDC for 4 hours at room temperature with 
gentle stirring. After that, the DR5 mAb were added into 
the nanoparticle suspension and incubated for 4 hours. 
After the conjugation reaction, the DTIC-NPs-DR5 mAb 
were puriﬁed by centrifugation (L-100XP) at 14,000 
rpm × 30 minutes and redispersed in phosphate-buffered 
solution. Finally, DTIC-NPs-DR5 mAb were washed 
with phosphate-buffered solution several times and 
lyophilized.
Characterization of antibody-modiﬁed  
nanoparticles
Freeze-dried nanoparticles were dispersed in deionized 
water (pH 7.0). Average size and zeta potential of the 
DTIC-NPs and DTIC-NPs-DR5 mAb were analyzed using a 
dynamic light-scattering detector (Zeta sizer ZS90, Malvern, 
Worcestershire, UK). At least three different batches were 
analyzed to give an average value and standard deviation 
for particle diameter and zeta potential. Morphological 
examination of DTIC-NPs-DR5 mAb was performed using 
transmission electron microscopy. Briefly, after the DTIC-
NPs-DR5 mAb were lyophilized, the dried nanoparticles 
were resuspended with deionized water. Samples were 
prepared by placing one drop of dilute dispersion onto a 
copper grid coated with a carbon membrane. The surface 
morphology of the DTIC-NPs-DR5 mAb samples was then 
visualized by transmission electron microscopy (H600, 
Hitachi, Tokyo, Japan).
evaluation of drug contents
The  concentration  of  DTIC  was  determined  by 
high-performance liquid chromatography (Hitachi D-2000). 
Chromatographic separations were performed on a reversed 
phase-C18 column (4.6 mm × 200 mm, 5 µm, Dikma analysis 
column). Methanol/water (30/70, v/v) was used as the eluent 
at a flow rate of 1 mL/min. The detection wavelength was 
319 nm. Drug loading and entrapment efﬁciency were 
determined as follows. Briefly, 10 mg of DTIC-NPs were 
introduced into Eppendorf tubes and dissolved in 1 mL 
acetonitrile and diluted by 0.1 M citric acid. Meanwhile, 
the amount of DTIC in the solution was determined by 
high-performance liquid chromatography. Drug loading and 
encapsulation efﬁciency of the drug-loaded nanoparticles 
were calculated according to equations (1) and (2):
 Drug loading (%) =
amount of the drug in NPs
amount of the NP Ps
100% ×
 
(1)
Encapsulatione fficiency
amount of the drug in NPs
amount
(%)
=
   of the feeding drug
× 100%
  (2)
In vitro release study
The in vitro release proﬁle of DTIC from DTIC-NPs-DR5 
mAb was determined by measuring the residual amount of 
DTIC present in the nanoparticles. For that purpose, several 
1 mL aliquots of the same DTIC-NPs-DR5 mAb suspension 
were diluted with   phosphate-buffered solution (pH 7.4, ﬁnal International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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volume 20 mL) in a capped centrifuge tube. The tubes were 
incubated at 37°C and shaken horizontally at 120 strokes/
minute. At specified time periods (1–168 hours), three 
tubes of each formulation were withdrawn and centrifuged 
at 16,000 rpm and 4°C for 30 minutes (L-100XP) to obtain 
nanoparticle precipitation by centrifugal force. After remov-
ing the supernatant, the precipitation was washed twice with 
distilled water and lyophilized. The amounts of residual DTIC 
in the nanoparticles were determined by high-performance 
liquid chromatography using the same procedure as described 
above. The released drug was quantiﬁed and the cumulative 
release proﬁle with time was demonstrated. The amount of 
drug released over time was expressed as a percentage of the 
initial drug load in the nanoparticles.
Determination of Dr5 monoclonal 
antibodies on nanoparticle surface
PE-loaded nanoparticles conjugated with FITC-labeled 
DR5 mAb (PE-NPs-DR5 mAb-FITC) were redispersed 
in phosphate-buffered solution at pH 7.4. Localization 
of FITC and PE was observed using a Leica TCS SP2 
ultraviolet-visible confocal spectral microscope. PE-NPs 
were run as a control and the images were analyzed using 
Leica confocal software.
A dispersion of PE-NPs-DR5 mAb-FITC was introduced 
directly into a flow cytometer and analyzed using a FACScan 
flow cytometer (Becton Dickinson, San Jose, CA) as 
described elsewhere.35 As a control, PE-NPs without FITC-
labeled DR5 mAb were also analyzed.
Quantiﬁcation of DR5 mAb conjugated  
with nanoparticles
The amount of DR5 mAb bound onto the nanoparticle sur-
face was quantiﬁed using the micro bicinchoninic acid assay 
method. Micro bicinchoninic acid working solution 1 mL 
was added to a 1 mL phosphate-buffered solution (pH 7.4) 
dispersion of DTIC-NPs-DR5 mAb (2.5 mg/mL) and DTIC-
NPs (2.5 mg/mL) as blank. After 60 minutes of incubation, 
the absorbance was measured at 570 nm using a microplate 
reader. The results were compared with a standard curve of 
DR5 mAb solution in phosphate-buffered solution (pH 7.4) 
ranging from 1 µg/mL to 40 µg/mL.
In vitro experiments
Human malignant melanoma A375 cell lines and mice 
ﬁbroblast NIH cell lines were cultivated in monolayers to 
80% confluence in Dulbecco’s modiﬁed Eagle’s medium 
supplemented with 10% fetal bovine serum at 37°C in 
a humidiﬁed environment of 5% CO2. The medium was 
replenished every other day and the cells were subcultured 
after reaching confluence.
To observe the binding ability and speciﬁcity of antibody-
modiﬁed nanoparticles to DR5-overexpressing A375 cells 
and DR5-negative NIH cells, a 1 × 106 cell suspension was 
incubated with PE-NPs-DR5 mAb-FITC (1 mg/mL) for 
60 minutes at 37°C, with untreated cells used as a negative 
control. To examine further the speciﬁcity of antibody-
modiﬁed nanoparticles to A375, a 1 × 106 cell suspension 
was treated with DR5 mAb for 30 minutes at 37°C, before 
incubation with 1 mg PE-NPs-DR5 mAb-FITC in 1 mL 
culture medium for 60 minutes at 37°C, the cells were then 
pelleted by centrifugation. Thereafter, the cells were washed 
and analyzed by FACScan flow cytometer.
cellular binding and uptake of  
antibody-modiﬁed nanoparticles
Cellular binding and uptake of PE-NPs-DR5 mAb-FITC 
in DR5-overexpressing and DR5-negative cell lines were 
examined by laser scanning confocal microscopy. In brief, 
5 × 105 A375 and NIH cells were incubated overnight in 
media at 37°C in each well of 24-well plates before incuba-
tion with the PE-NPs-DR5 mAb-FITC for varying times 
at 37°C (untreated cells were used as controls), and then 
washed three times with phosphate-buffered solution, fol-
lowed by ﬁxation with 4% p-formaldehyde for 15 minutes. 
Afterwards, Hoechst 33342 (Invitrogen, Carlsbad, CA) was 
used to counterstain the nuclei of the cells. Finally, the cells 
were imaged using Leica TCS SP2 ultraviolet-visible confo-
cal spectral microscopy, and the images were analyzed using 
Leica confocal software.
In vitro cytotoxicity
Cytotoxicity was analyzed using a Cell Titer 96 nonradioactive 
cell proliferation assay kit according to the manufacturer’s 
protocol (Promega, Madison, WI).36 Briefly, A375 cells and 
NIH cells (5 × 103) were cultured for 24 hours before treat-
ment. Cells were then treated with various concentrations of 
free DTIC, DR5 mAb, DTIC-NPs, NPs-DR5 mAb, DTIC-
NPs + DR5 mAb and DTIC-NPs-DR5 mAb for 3 days at 
37°C in a CO2 incubator. The concentrations of DTIC and 
DR5 mAb used in this assay were varied from 0.001–8 µg/mL 
and 0.0008–5.8 µg/mL (equivalent to PLA concentration of 
up to about 0.5 mg/mL). NIH cells (5 × 103) were treated 
with drug-free PLA nanoparticles (PLA-NPs) and drug-free 
PLA-DR5 mAb nanoparticles (PLA-NPs-DR5 mAb) with 
different concentrations (137.5–2200 µg/mL) to evaluate International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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the cytotoxicity of the drug delivery system. Then, 20 µL of 
MTT reagent 5 mg/mL was added to each well, followed by 
150 µL of dimethyl sulfoxide to dissolve the crystal 4 hours 
later. The absorbance of each well was measured at 570 nm 
using a microplate reader. Viability of untreated cells was set 
at 100%, and absorbance of wells with medium and without 
cells was set as zero. All of the results were from at least 
triplicate experiments.
Detection of cell apoptosis
A375 cells (1 × 105 cells/well) were preincubated in 24-well 
plates and incubated at 37°C in a 5% CO2 incubator for 
24 hours after treatment with DTIC 64 µg/mL. DR5 mAb 
(46 µg/mL) or DTIC-NPs, NPs-DR5 mAb, DTIC-NPs + 
DR5 mAb and DTIC-NPs-DR5 mAb were loaded with the 
same amount of DTIC and DR5 mAb (untreated cells were 
used as controls) for 72 hours. The cells were washed with 
0.1 M phosphate-buffered solution, trypsinized, and centri-
fuged. The cell pellet was then resuspended in 490 µL of the 
cold binding buffer, and aliquots of 5 µL of diluted Annexin 
V-FITC and propidium iodide solutions were added to the 
tubes containing 490 µL of the A375 malignant melanoma 
cell suspensions. The mixtures were then vortexed for ﬁve 
seconds and kept for 10 minutes on ice in the dark. After the 
incubation, the cell samples were analyzed by FACScan flow 
cytometer. The tests were carried out in triplicate.
Data analysis
The data were presented as mean ± standard deviation. 
  Statistical signiﬁcance was determined using the two-sample 
t-test and analysis of variance, with P , 0.05 as the signiﬁ-
cance level.
Results
Particle size, zeta potential, and 
morphology
In the present study, nanoparticles were prepared from a 
PLA polymer, using a modiﬁed double emulsion solvent 
evaporation method. Because nanoparticle size is important 
for developing drug delivery strategies at speciﬁc sites in 
the body, smaller nanoparticles may be prone to minimal 
particle uptake by nontargeted cells, including premature 
clearance by the mononuclear phagocytic system.37 An 
orthogonal design was used to optimize the preparation 
technology on the basis of single factor evaluation. Optimal 
concentrations for preparation of the nanoparticles were 
10 mg/mL for PLA and 3 mg/mL for DTIC. The methylene 
dichloride:acetone ratio was 3:2 (v/v), the concentration of 
human serum albumin was 1%, and the volume ratio of o/w 
was 1/10 (v/v).
The resulting DTIC-NPs were sized at 152.2 ± 5.7 nm 
(n = 6), with a relatively monodispersed size (polydispersity 
index , 0.3, Table 1 and Figure 1A), which was not much 
larger than for the drug-free nanoparticles (138.0 ± 3.6 nm). 
However, there was an approximately 20 nm increase in the 
particle size of DTIC-NPs-DR5 mAb (174.0 ± 4.1 nm) as 
compared with DTIC nanoparticles, presumably owing to the 
presence of DR5 mAb on the nanoparticle surface. The mean 
zeta potential of the DTIC-NPs was −30.1 ± 1.9 mV (n = 6), 
whereas the mean zeta potential of the DTIC-NPs-DR5 mAb 
was −34.6 ± 2.3 mV (n = 6, Table 1 and   Figure1B). It was 
further demonstrated that the increase in zeta potential may 
be attributed to the presence of DR5 mAb on the nanoparticle 
surface. As shown in   Figure 1C, the dried nanoparticles were 
easily resuspended and well dispersed in water or phosphate-
buffered solution. From Figure 1D and E, we could see that 
the targeted modiﬁed nanoparticles have the same spherical 
shape without any adhesion or aggregation, indicating that 
the nanoparticles were stable during the mAb conjugation 
process on the surface of the nanoparticles.
evaluation of drug contents
We optimized the study formulations to control the size of 
nanoparticles as described above. Drug content also plays a 
critical role in targeted drug delivery. To obtain the large drug 
loading required to meet therapeutic needs, a high concentration 
of DTIC (about 3 mg/mL, DTIC solubility about 4 mg/mL) was 
chosen as the concentration for the inner water phase. DTIC-
NPs with a drug loading of 17.8 ± 0.8 µg/mg (n = 3) and an 
encapsulation efﬁciency of 71.7% ± 2.5% (n = 3) were used 
in subsequent experiments unless otherwise stated.
In vitro release study
The release proﬁle in vitro was evaluated. A sustained 
release pattern was visible when DTIC was released from 
  DTIC-DR5 mAb nanoparticles, as shown in Figure 2. The 
release behavior of DTIC from the polymer matrix showed 
a biphasic pattern characterized by a burst release in the ﬁrst 
Table 1 The particle size and zeta potential of NPs
Drug-free  
NPs
DTIC-NPs DTIC-NPs- 
DR5 mAb
size 138.0 ± 3.6 nm 152.2 ± 5.7 nm 174.0 ± 4.1 nm
Zeta potential −22.6 ± 2.6 mV −30.1 ± 1.9 mV –34.6 ± 2.3 mV
Note: Data are expressed as the mean ± sD (n = 6).
Abbreviations: DTIc, dacarbazine; mAb, monoclonal antibody; NPs, nanoparticles; 
sD, standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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4 hours, which can be ascribed to the drug being located in 
or close to the nanoparticle surface, followed by a slower and 
continuous release. About 45% of the DTIC was released from 
the nanoparticles within 24 hours, and cumulative release was 
up to 80% at 72 hours. After that, a slower release rate could 
be observed, and nearly 90% DTIC was released in 7 days.
Determination of Dr5 monoclonal 
antibodies on nanoparticle surface
Binding of DR5 mAb to the nanoparticle surface was evalu-
ated by laser scanning confocal microscopy (Figure 3). The 
FITC-labeled DR5 mAb-modiﬁed PE nanoparticles showed 
both red fluorescence (Figure 3B, represents the nanopar-
ticles) and green fluorescence (Figure 3C, represents the 
DR5 mAb), and merged red/green fluorescence (Figure 3D) 
indicates that the nanoparticles were successfully coupled 
with DR5 mAb. In contrast, nanoparticles without mAb only 
showed red fluorescence (Figure 3A).
The conjugation of DR5 mAb to the nanoparticle surface 
was also conﬁrmed by flow cytometry. As shown in density 
plots (Figure 3E and F), unlike the nanoparticles without 
antibodies, the antibody-modiﬁed nanoparticles showed green 
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fluorescence, indicating that nearly all nanoparticles were 
coupled with DR5 mAb through the conjugation reaction, and 
that the population of antibody-modiﬁed nanoparticles was 
rather homogeneous. A shift of FITC fluorescence intensity 
could be seen for antibody-modiﬁed nanoparticles (light 
green line) in comparison with nanoparticles without mAb 
(dark green line), indicating the presence of FITC-labeled 
DR5 mAb on the surface of the nanoparticles (Figure 3G).
The protein assay was used to quantify the amount of 
bound DR5 mAb on the nanoparticle surface. Because this 
assay cannot distinguish bound DR5 mAb from human serum 
albumin on the surface of nanoparticles, DTIC-NPs were run 
as a control. According to the protein assay, the amount of 
conjugated DR5 mAb on the antibody-modiﬁed nanoparticles 
was shown to be approximately 12.8 ± 2.4 µg DR5 mAb/mg 
nanoparticles (n = 4).
recognition and binding properties of 
antibody-modiﬁed nanoparticles
That the biological recognition activity of the targeting ligand 
is not destroyed in the conjugation procedure is key to the 
antibody-modiﬁed nanoparticles targeting the desired cell. We 
utilized flow cytometry to conﬁrm the recognition properties of 
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Abbreviations: DTIc, dacarbazine; mAb, monoclonal antibody; NPs, nanoparticles; PE, phycoerythrin; FITC, ﬂuorescein isothiocyanate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1998
Ding et al
0
01 02 103 104
PE-NPs-DR5 mAb-FITC Control
105
100
200
C
o
u
n
t
s
A375 cells
300
400
A
0
01 02 103 104
PE-NPs-DR5 mAb-FITC Control
105
100
200
C
o
u
n
t
s
NIH cells
Fluorescence intensity
300
400
B
0
01 02 103 104
PE-NPs-DR5 mAb-FITC
DR5 MAb + PE-NPs--DR5 mAb-FITC
Control
105
100
200
C
o
u
n
t
s
A375 cells
300
400
C
Figure 4 (A and B) Fluorescence intensity histogram of A375 cells and NIh cells treated by Pe-NPs-Dr5 mAb-FITc, untreated cells were used as negative control. (C) 
Fluorescence intensity histogram of A375 cells treated by Dr5 mAb before the adding of Pe-NPs-Dr5 mAb-FITc, untreated cells and cells not pretreated with Dr5 mAb 
were used as negative and positive controls, respectively. 
Abbreviations: DTIc, dacarbazine; mAb, monoclonal antibody; NPs, nanoparticles; PE, phycoerythrin; FITC, ﬂuorescein isothiocyanate.
PE-NPs-DR5 mAb-FITC for DR5. As shown in Figure 4A and 
B, in contrast with NIH cells, PE-NPs-DR5 mAb-FITC-treated 
A375 cells had an apparent rightward shift of the fluorescence 
in the histogram compared with untreated cells, which indicated 
that DR5 antibody-modiﬁed nanoparticles possess a potent 
binding afﬁnity for DR5-overexpressing A375 cells, but nearly 
no binding afﬁnity for DR5-negative NIH cells (the slight 
fluorescence detected might have been caused by only a few 
nanoparticles being internalized into the cells by endocytosis or 
phagocytosis). In order to demonstrate further the speciﬁcity of 
the interaction of DTIC-NPs-DR5 mAb with the targeted cells, 
a competitive assay was performed using free DR5 mAb. As 
shown in Figure 4C, unlike the obviously fluorescent rightward 
shift of cells not pretreated with DR5 mAb, the rightward shift 
of the fluorescence in the histogram of cells pretreated with 
DR5 antibodies compared with untreated cells was slight, 
indicating that binding of DTIC-NPs-DR5 mAb to A375 cells 
was competitively inhibited by DR5 mAb, which demonstrates 
that the DTIC-NPs-DR5 mAb were internalized mainly by a 
ligand-mediated mechanism.
The flow cytometry results demonstrated that DR5 mAb 
were effectively conjugated to the nanoparticle surface with 
preserved biological activity during the process of covalent 
conjugation.
cellular binding and uptake of  
antibody-modiﬁed nanoparticles
Confocal microscopy was used to conﬁrm cellular uptake 
efﬁciency and intracellular distribution of the antibody-
modiﬁed nanoparticles. Internalization of PE-DR5 mAb-FITC 
nanoparticles would lead to localized green FITC staining in 
the cytoplasm. After incubation with PE-DR5 mAb nano-
particles for different times, FITC and PE fluorescence was 
detected only on the A375 cell surface after 5 minutes of incu-
bation. After a 30-minute incubation, FITC fluorescence and 
PE fluorescence were detected in the cytoplasm of all cells, and 
when incubated for 60 minutes, most of the PE nanoparticles 
were uptaken into the cells (Figure 5A). In contrast, when 
incubated with DR5-negative NIH cells for 1 hour (Figure 5B), 
no signiﬁcant FITC fluorescence was detected, which is con-
sistent with the above result for cellular binding. In the case 
of DR5 mAb nanoparticles, ligand-receptor recognition could 
help to increase internalization of the nanoparticles.
In vitro cytotoxicity assays
The in vitro cytotoxicity of the nanoparticles was tested using 
an MTT assay in NIH cells treated with increasing doses of 
PLA nanoparticles and DTIC-NPs-DR5 mAb which did not 
encapsulate DTIC. The nanoparticles were found to be nontoxic 
at each of the tested concentrations. We did not observe a 
signiﬁcant difference in the toxicity of DTIC-NPs and DTIC-
NPs-DR5 mAb, although there was a slight reduction in cell 
viability at higher concentrations. Average cell viability ranged 
from 80.1% ± 3.9% to 93.5% ± 2.4% (n = 3) of control viability 
at the concentrations studied, suggesting that DTIC-NPs-DR5 
mAb may be used as a target carrier (Figure 6).
The cytotoxic activity of DTIC-NPs-DR5 mAb against 
A375 and NIH cells was evaluated by MTT assay (untreated 
A375 or NIH cells were used as controls). As shown in 
Figure 7, A375 cells, which express high levels of DR5, 
were most sensitive to DTIC-NPs-DR5 mAb. However, the 
DR5-negative NIH cells were much less sensitive to DTIC-International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Figure 5 Binding and uptake of antibody modiﬁed nanoparticles. Binding and uptake analysis of PE-NPs-DR5 mAb-FITC were taken by confocal laser scanning microscopy. 
(A) A375 cells, with an incubation time of 5 minutes, 30 minutes, and 1 hour, (B) NIh cells had an incubation time of 1 hour. cells were imaged by Leica Tcs sP2 ultraviolet-
visible confocal spectral microscope and the images were analyzed by Leica confocal software.
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NPs-DR5 mAb. Similar results were obtained when the two 
cell lines were incubated with drug-free DR5 mAb nano-
particles, suggesting that the binding ability and speciﬁcity 
of DTIC-NPs-DR5 mAb and NPs-DR5 mAb for DR5 were 
critical for induction of cytotoxicity (Figure 8). It was clearly 
shown that   DTIC-NPs-DR5 mAb were more cytotoxic to 
A375 cells when compared with DTIC, DR5 mAb, DTIC 
nanoparticles, NPs-DR5 mAb and DTIC-NPs + DR5 mAb. 
Incubation of the cells with free DTIC contributed to a 
smaller reduction in cell viability compared with the same 
concentration of drug provided by PLA nanoparticles. It might 
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Figure 6 cytotoxicity of PLA-NPs and PLA-NPs-Dr5 mAb in NIh cells. The cells were incubated using different concentrations of NPs in the range from 137.5 µg/mL to 
2200 µg/mL for a time period of 24 hours (mean ± standard deviation; n = 5). 
Abbreviations: mAb, monoclonal antibody; NPs, nanoparticles; PE, phycoerythrin; FITC, ﬂuorescein isothiocyanate; PLA, polylactic acid.
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Notes: *P , 0.05; **P , 0.01; ***P , 0.001.
Abbreviations: DTIc, dacarbazine; mAb, monoclonal antibody; NPs, nanoparticles.
be related to the enhanced stability and improved cellular 
uptake of DTIC encapsulated by nanoparticles, which could 
also enable sustained chemotherapy. A mixture of DTIC-
NPs and free mAb showed increased cytotoxicity compared 
with free DTIC, free mAb, and DTIC nanoparticles, which 
might be because DTIC and DR5 mAb are able to induce 
cancer cell apoptosis through the intrinsic pathway and 
extrinsic pathway, respectively.   However, a mixture of DTIC 
nanoparticles with free mAb in the same amount as that 
conjugated to DTIC-DR5 mAb nanoparticles showed lower 
cytotoxic activity against A375 cells than DTIC-DR5 mAb International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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nanoparticles, indicating that the advanced cytotoxicity of 
DTIC-DR5 mAb nanoparticles was also dependent on the con-
jugated DR5 mAb.38 Compared with the other control groups, 
DTIC-DR5 mAb nanoparticles showed notably enhanced 
cytotoxicity against DR5-overexpressing cells. Therefore, the 
combination of speciﬁc targeting and drug loading in these 
nanoparticulate formulations could lead to improved cancer 
therapy. We speculate that the antitumor mechanism of DTIC-
DR5 mAb nanoparticles is their binding and internalization 
into tumor cells with subsequent intracellular release of DTIC 
after PLA degradation.
cell apoptosis
Cell apoptosis was evaluated by flow cytometry. Speciﬁcally, 
the A375 cells were treated for 72 hours with free DTIC, 
free DR5 mAb or DTIC nanoparticles, DTIC-+DR5 mAb 
nanoparticles, DTIC + DR5 mAb, as well as DTIC-DR5 mAb 
nanoparticles containing the same concentration of free DTIC 
and DR5 mAb. Apoptosis of A375 cells analyzed by FACScan 
flow cytometry is shown in Figure 9. Figure 10 shows the 
results of the statistical analysis for average cell apoptosis 
(%) induced by the various formulations. The apoptotic cells 
incubated with free DTIC and mAb were about 31.7% ± 3.9% 
and 24.9% ± 2.1% (n = 3), respectively. In contrast, the 
number of apoptotic cells increased to about 34.6% ± 4.2%, 
39.8% ± 4.1%, 44.7% ± 5.6%, and 58.5% ± 5.0% (n = 3) 
when the A375 cells were incubated with DTIC nanopar-
ticles, DTIC-DR5 mAb, DTIC-+DR5 mAb nanoparticles, 
and DTIC-DR5 mAb nanoparticles, respectively. Therefore, 
a mixture of free DTIC with free mAb or DTIC nanoparticles 
with free mAb may induce more cancer cell apoptosis when 
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Notes: *P , 0.05; **P , 0.01; ***P , 0.001. 
Abbreviations: DTIc, dacarbazine; mAb, monoclonal antibody; NPs, nanoparticles.
compared with the direct administration of free DTIC and 
free DR5 mAb, and this is more apparent when the cells 
were treated with DTIC-DR5 mAb nanoparticles that can 
bind speciﬁcally to DR5-positive A375 cells, which results 
in enhanced efﬁciency of intracellular delivery and apop-
totic effects of DTIC and DR5 mAb.
Discussion
The current treatment options for malignant melanoma are 
still not satisfactory for both patients and clinicians. Single-
agent or combination chemotherapy, new agents, or biologic 
response modiﬁers alone have not resulted in response rates 
or durable remissions that are high enough to affect median 
survival. There is an urgent need to develop new innova-
tive treatment options. Many current opportunities exist for 
improving the treatment of patients with melanoma, includ-
ing novel immunotherapy approaches, molecularly targeted 
treatments, and antiangiogenic therapies. Combinations of 
these new agents will likely be necessary to make progress 
in the treatment of the disease.39
In this study, we developed a new active targeting drug 
delivery system (DTIC-DR5 mAb nanoparticles) to combine 
chemotherapy and active speciﬁc immunotherapy in an 
optimal manner. DTIC is the only chemotherapeutic agent 
approved by the US Food and Drug Administration for the 
treatment of melanoma. So far, it is the most active single 
agent for treatment of metastatic melanoma.40,41 Among 
the existing therapeutic strategies for cancer, targeting the 
TRAIL pathway has been considered an attractive one in 
recent years due to its ability to induce apoptosis selectively 
in malignant cells while demonstrating little cytotoxic-International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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ity in normal cells.42 Early clinical trials have been initiated 
for the evaluation of mAb to DR4 or DR5, which have been 
shown to increase the in vitro cytotoxicity of standard chemo-
therapy drugs and to inhibit tumor growth in vivo in sensitive 
cell lines.43–45 Meanwhile, the difference in the level of DR5 
expression between normal cells and tumor cells suggest that 
DR4 or DR5 mAb can be used as a mediator for targeted drug 
delivery. Because DR4 or DR5 is abundantly expressed on the 
surface of malignant melanoma cells,46,47 it can be expected 
that DR4 or DR5 mAb will be very promising bioactive 
immunotherapeutic molecules in malignant melanoma. Thus, 
in this research, DTIC, which induces apoptosis through the 
intrinsic pathway, was used as a model drug to prepare DTIC-
NPs, which were covalently conjugated with highly speciﬁc 
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Figure 9 A375 cells apoptosis analyzed by FACScan ﬂow cytometer. (A) Untreated A375 cells were used as controls. (B–G) Pictures are representative results from ﬂow 
cytometry of propidium iodine and Annexin V-FITc-stained A375 cells treated with free DTIc, free Dr5 mAb or DTIc-NPs, DTIc-NPs + Dr5 mAb, DTIc + Dr5 mAb, 
DTIc-NPs − Dr5 mAb (loaded with the same amount of DTIc and Dr5 mAb for 72 hours). 
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targeting of functional DR5 mAb that can contribute directly 
to apoptosis or growth inhibition of cancer cells through the 
extrinsic pathway, thereby obtaining an active targeting drug 
delivery system, ie, DTIC-NPs-DR5 mAb.
In the present work, biodegradable PLA polymers 
with great compatibility were utilized to prepare DTIC-
NPs using a modified w/o/w double emulsion-solvent 
evaporation method by ultrasonic processing without any 
additional additives. Polymerizer encapsulation could 
enhance the stability of DTIC and decrease its nonspeciﬁc 
toxicity. Furthermore, regulated drug release from the 
nanoparticles may reduce or eliminate tissue damage on 
accidental extravasation.20 Nanoparticles with a small size 
of 100–200 nm are prone to minimizing particle uptake 
by nontargeted cells, including their premature clearance 
by the mononuclear phagocytic system, resulting in a long 
circulation time in vivo.37,48 The DTIC-NPs and DTIC-NPs-
DR5 mAb prepared in this study were sized at about 150 nm 
and 170 nm, respectively, which were within the scope of 
the ideal size between 100 and 200 nm) as mentioned above. 
The antibody conjugation reaction was performed at a low 
temperature using EDC as the coupling agent, which not 
only ensures the stability of DR5 mAb but also preserves 
the immunoreactivity of DR5 mAb. The DR5 mAb was 
conjugated onto the surface of the nanoparticles instead of 
being directly conjugated with DTIC, so the activity of DTIC 
was also well preserved during preparation. The experimen-
tal results demonstrated that DTIC-NPs-DR5 mAb retained 
their speciﬁc binding activity to DR5 and could be almost 
completely internalized into DR5-overexpressing cells. The 
superior targeting of DTIC-NPs-DR5 mAb was attributed 
to more cellular uptake by tumor cells, which was mediated 
by ligand-receptor recognition.
The results demonstrated that the DTIC-NPs-DR5 mAb 
had improved antitumor activity, increased cell apoptosis 
in DR5-positive malignant melanoma cells, and minimal 
toxicity to DR5-negative cells. The mechanism by which 
the effective antitumor activity of DTIC-NPs-DR5 mAb 
can be achieved might also contribute to the three-phase 
delivery of the targeted nanoparticles. In the ﬁrst phase, the 
nanoparticles slowly accumulate in tumor cells, ultimately 
reaching high tumor levels due to the enhanced permeability 
and retention effect.20 In the second phase, the targeted 
nanoparticle binding and internalization into tumor cells 
might be associated with DR5 mAb on the surface of the 
nanoparticles, which initiates receptor-mediated endocytosis 
by binding to DR5 in the cell membrane and then the 
loaded DTIC is released to kill cells.49 In the third phase, 
the DR5 mAb exhibits bispeciﬁc properties of selectively 
binding to DR5-positive cancer cells and inducing apoptosis 
of cancer cells through the extrinsic pathway. DTIC and 
DR5 mAb in the active targeting delivery system induce 
apoptosis of cancer cells through the intrinsic pathway and 
the extrinsic pathway, respectively, and may increase the sen-
sitivity of cancer cells to the cytotoxic effects of the chemical 
drug as well as the antibody. Thus, not only free DR5 mAb 
but also DR5 mAb-modiﬁed drug-loaded nanoparticles could 
have a role in tumor therapy.
Conclusion
The present study describes a new therapeutic strategy of 
chemotherapy and immunotherapy for malignant mela-
noma. Modiﬁed DTIC-loaded PLA nanoparticles mediated 
by DR5 mAb were successfully prepared and evaluated 
in detail. For the ﬁrst time, we used biodegradable PLA 
polymers to develop small-sized DTIC nanoparticles and 
conjugated targeted ligand DR5 mAb, which has anticancer 
biological activity itself, onto the surface of nanoparticles 
via conjugation to form antibody-modiﬁed nanoparticles. 
In vitro experiments demonstrated that the DTIC-NPs-DR5 
mAb drug targeting system can speciﬁcally target DR5-
overexpressing malignant melanoma cells and become 
internalized efﬁciently. Most strikingly, compared with 
conventional DTIC-NPs, DTIC-NPs-DR5 mAb show sig-
niﬁcantly enhanced antitumor activity, increased cancer cell 
apoptosis, and decreased nonspeciﬁc toxicity.
These results suggest that DTIC-NPs-DR5 mAb could 
be used as an efﬁcient targeted delivery system. This new 
chemoimmunotherapeutic approach might be a valuable 
treatment for DR5-overexpressing malignant melanoma 
with fewer side effects than conventional cytotoxins. 
The outcome of such chemoimmunotherapy is profound 
because the use of the antibody directly contributes to the 
inhibition of cell growth and cell death. It is conceivable 
that this novel nanotechnology could be applied to other 
cytotoxins.
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